Amneet Sandhu
Concepts (201)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atrial Fibrillation | 15 | 2025 | 390 | 6.990 |
Why?
| | Catheter Ablation | 13 | 2025 | 349 | 4.240 |
Why?
| | Pacemaker, Artificial | 6 | 2025 | 119 | 2.750 |
Why?
| | Atrial Appendage | 3 | 2024 | 17 | 2.420 |
Why?
| | Defibrillators, Implantable | 8 | 2025 | 315 | 2.250 |
Why?
| | Transcatheter Aortic Valve Replacement | 5 | 2023 | 130 | 2.130 |
Why?
| | Aortic Valve Stenosis | 5 | 2023 | 229 | 1.630 |
Why?
| | Stroke | 4 | 2024 | 1134 | 1.460 |
Why?
| | Anticoagulants | 6 | 2025 | 662 | 1.420 |
Why?
| | Cardiac Resynchronization Therapy | 3 | 2021 | 46 | 1.370 |
Why?
| | Percutaneous Coronary Intervention | 5 | 2017 | 478 | 1.350 |
Why?
| | Ventricular Premature Complexes | 5 | 2025 | 36 | 1.340 |
Why?
| | Arrhythmias, Cardiac | 4 | 2021 | 333 | 1.330 |
Why?
| | Tachycardia, Ventricular | 7 | 2022 | 175 | 1.170 |
Why?
| | Ventricular Dysfunction, Left | 4 | 2025 | 389 | 1.150 |
Why?
| | Coronary Stenosis | 2 | 2017 | 38 | 1.000 |
Why?
| | Hospitals | 4 | 2019 | 689 | 0.930 |
Why?
| | Tachycardia, Atrioventricular Nodal Reentry | 2 | 2021 | 30 | 0.860 |
Why?
| | Heart Atria | 3 | 2024 | 136 | 0.820 |
Why?
| | Aortic Valve | 5 | 2023 | 352 | 0.810 |
Why?
| | Pericardial Effusion | 1 | 2022 | 23 | 0.800 |
Why?
| | Risk Factors | 17 | 2025 | 10368 | 0.710 |
Why?
| | Electrophysiologic Techniques, Cardiac | 2 | 2019 | 82 | 0.710 |
Why?
| | Esophagus | 2 | 2023 | 255 | 0.690 |
Why?
| | Coronary Sinus | 1 | 2020 | 7 | 0.690 |
Why?
| | Therapeutic Irrigation | 2 | 2019 | 79 | 0.670 |
Why?
| | Patient Discharge | 2 | 2025 | 906 | 0.670 |
Why?
| | Treatment Outcome | 14 | 2025 | 10800 | 0.670 |
Why?
| | Cardiac Catheterization | 2 | 2022 | 528 | 0.660 |
Why?
| | Shock | 1 | 2020 | 95 | 0.640 |
Why?
| | Length of Stay | 1 | 2025 | 1218 | 0.620 |
Why?
| | Coronary Artery Disease | 3 | 2014 | 703 | 0.620 |
Why?
| | Esophageal Fistula | 1 | 2019 | 19 | 0.620 |
Why?
| | Registries | 9 | 2025 | 2016 | 0.600 |
Why?
| | Humans | 52 | 2025 | 137294 | 0.580 |
Why?
| | Postoperative Complications | 5 | 2019 | 2658 | 0.580 |
Why?
| | Heart Block | 1 | 2018 | 42 | 0.570 |
Why?
| | Administration, Oral | 3 | 2025 | 812 | 0.550 |
Why?
| | Electrocardiography | 6 | 2023 | 630 | 0.540 |
Why?
| | Cryosurgery | 1 | 2018 | 59 | 0.540 |
Why?
| | Tetralogy of Fallot | 1 | 2018 | 78 | 0.540 |
Why?
| | Practice Patterns, Physicians' | 2 | 2017 | 1302 | 0.520 |
Why?
| | Heart Valve Prosthesis | 1 | 2018 | 116 | 0.510 |
Why?
| | Tilidine | 1 | 2016 | 2 | 0.510 |
Why?
| | Pulmonary Valve | 1 | 2018 | 98 | 0.500 |
Why?
| | Aged | 24 | 2025 | 23851 | 0.500 |
Why?
| | Oxycodone | 1 | 2016 | 44 | 0.490 |
Why?
| | Coronary Artery Bypass | 1 | 2017 | 238 | 0.480 |
Why?
| | Preoperative Care | 1 | 2018 | 358 | 0.480 |
Why?
| | Assisted Circulation | 1 | 2015 | 26 | 0.480 |
Why?
| | Antihypertensive Agents | 2 | 2019 | 488 | 0.480 |
Why?
| | Male | 31 | 2025 | 67560 | 0.470 |
Why?
| | Naloxone | 1 | 2016 | 120 | 0.460 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2017 | 256 | 0.440 |
Why?
| | Middle Aged | 22 | 2025 | 33310 | 0.440 |
Why?
| | Plaque, Atherosclerotic | 1 | 2014 | 57 | 0.430 |
Why?
| | United States | 10 | 2025 | 14742 | 0.430 |
Why?
| | Blue Cross Blue Shield Insurance Plans | 1 | 2013 | 2 | 0.420 |
Why?
| | Prescriptions | 2 | 2023 | 67 | 0.410 |
Why?
| | United States Department of Veterans Affairs | 1 | 2017 | 676 | 0.410 |
Why?
| | Cardiomyopathies | 3 | 2025 | 350 | 0.410 |
Why?
| | Hospitals, Teaching | 1 | 2013 | 116 | 0.400 |
Why?
| | Retrospective Studies | 17 | 2025 | 15639 | 0.400 |
Why?
| | Atrial Flutter | 2 | 2024 | 36 | 0.390 |
Why?
| | Thiophenes | 1 | 2013 | 118 | 0.390 |
Why?
| | Cardiac Surgical Procedures | 1 | 2018 | 530 | 0.380 |
Why?
| | Tachycardia, Supraventricular | 2 | 2022 | 43 | 0.370 |
Why?
| | Female | 28 | 2025 | 73052 | 0.370 |
Why?
| | Time Factors | 9 | 2025 | 6818 | 0.360 |
Why?
| | Heart Failure | 4 | 2021 | 2234 | 0.350 |
Why?
| | Healthcare Disparities | 1 | 2017 | 652 | 0.350 |
Why?
| | Patient Participation | 2 | 2024 | 417 | 0.340 |
Why?
| | Piperazines | 1 | 2013 | 350 | 0.340 |
Why?
| | Atrioventricular Block | 2 | 2021 | 37 | 0.330 |
Why?
| | Hypertension | 2 | 2019 | 1285 | 0.330 |
Why?
| | Acute Coronary Syndrome | 1 | 2013 | 275 | 0.320 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2013 | 461 | 0.310 |
Why?
| | Tomography, X-Ray Computed | 1 | 2019 | 2679 | 0.300 |
Why?
| | Cost-Benefit Analysis | 2 | 2022 | 586 | 0.280 |
Why?
| | Bundle-Branch Block | 3 | 2023 | 31 | 0.280 |
Why?
| | Heart Conduction System | 2 | 2024 | 101 | 0.250 |
Why?
| | Cardiac Pacing, Artificial | 2 | 2023 | 87 | 0.250 |
Why?
| | Electric Countershock | 3 | 2023 | 107 | 0.240 |
Why?
| | Cardiovascular Diseases | 2 | 2024 | 2113 | 0.230 |
Why?
| | Heart Defects, Congenital | 2 | 2022 | 834 | 0.230 |
Why?
| | Clinical Decision-Making | 2 | 2024 | 319 | 0.230 |
Why?
| | Thromboembolism | 1 | 2025 | 119 | 0.220 |
Why?
| | Government Regulation | 1 | 2024 | 54 | 0.220 |
Why?
| | Off-Label Use | 1 | 2023 | 52 | 0.210 |
Why?
| | Death, Sudden, Cardiac | 2 | 2021 | 185 | 0.200 |
Why?
| | Risk Assessment | 5 | 2024 | 3439 | 0.200 |
Why?
| | Transposition of Great Vessels | 1 | 2022 | 36 | 0.190 |
Why?
| | Guideline Adherence | 2 | 2019 | 549 | 0.190 |
Why?
| | Sweden | 1 | 2022 | 101 | 0.190 |
Why?
| | Pulmonary Veins | 1 | 2022 | 99 | 0.180 |
Why?
| | Rivaroxaban | 1 | 2023 | 254 | 0.180 |
Why?
| | Prospective Studies | 5 | 2019 | 7595 | 0.180 |
Why?
| | Aged, 80 and over | 4 | 2019 | 7607 | 0.180 |
Why?
| | Accessory Atrioventricular Bundle | 1 | 2020 | 13 | 0.170 |
Why?
| | Ventricular Fibrillation | 1 | 2020 | 60 | 0.170 |
Why?
| | Bradycardia | 1 | 2021 | 55 | 0.170 |
Why?
| | Swine | 1 | 2023 | 774 | 0.170 |
Why?
| | Cardiac Catheters | 1 | 2019 | 15 | 0.160 |
Why?
| | Death | 1 | 2020 | 118 | 0.160 |
Why?
| | Follow-Up Studies | 5 | 2024 | 5125 | 0.160 |
Why?
| | Papillary Muscles | 1 | 2019 | 13 | 0.160 |
Why?
| | Temperature | 1 | 2023 | 677 | 0.160 |
Why?
| | Coffee | 1 | 2019 | 17 | 0.160 |
Why?
| | Tricuspid Valve Insufficiency | 1 | 2019 | 24 | 0.160 |
Why?
| | Electrodes | 1 | 2019 | 113 | 0.160 |
Why?
| | Aortic Valve Insufficiency | 1 | 2019 | 47 | 0.160 |
Why?
| | Technology | 1 | 2020 | 96 | 0.160 |
Why?
| | Inpatients | 1 | 2023 | 503 | 0.150 |
Why?
| | Diffusion of Innovation | 1 | 2019 | 98 | 0.150 |
Why?
| | Ventricular Function, Left | 2 | 2020 | 540 | 0.150 |
Why?
| | Electrocardiography, Ambulatory | 1 | 2019 | 63 | 0.150 |
Why?
| | Action Potentials | 2 | 2019 | 495 | 0.150 |
Why?
| | Mitral Valve Insufficiency | 1 | 2019 | 69 | 0.150 |
Why?
| | Practice Guidelines as Topic | 2 | 2019 | 1577 | 0.150 |
Why?
| | Heart Valve Diseases | 1 | 2020 | 152 | 0.150 |
Why?
| | Heparin | 1 | 2020 | 259 | 0.150 |
Why?
| | Heart Rate | 2 | 2019 | 823 | 0.150 |
Why?
| | Coronary Angiography | 2 | 2017 | 312 | 0.140 |
Why?
| | Prosthesis Implantation | 1 | 2019 | 154 | 0.140 |
Why?
| | Myocardial Infarction | 2 | 2016 | 1045 | 0.140 |
Why?
| | Equipment Design | 1 | 2019 | 522 | 0.140 |
Why?
| | Echocardiography, Stress | 1 | 2017 | 25 | 0.140 |
Why?
| | Decision Support Techniques | 1 | 2021 | 418 | 0.140 |
Why?
| | Adult | 7 | 2023 | 37724 | 0.140 |
Why?
| | Sarcoidosis | 1 | 2019 | 159 | 0.130 |
Why?
| | Ventricular Function, Right | 1 | 2019 | 283 | 0.130 |
Why?
| | Anti-Arrhythmia Agents | 3 | 2023 | 114 | 0.130 |
Why?
| | Pharmacovigilance | 1 | 2016 | 23 | 0.130 |
Why?
| | Hot Temperature | 1 | 2019 | 394 | 0.120 |
Why?
| | Diagnosis, Differential | 1 | 2020 | 1484 | 0.120 |
Why?
| | Intra-Aortic Balloon Pumping | 1 | 2015 | 17 | 0.120 |
Why?
| | Predictive Value of Tests | 2 | 2019 | 2032 | 0.120 |
Why?
| | World Health Organization | 1 | 2016 | 123 | 0.120 |
Why?
| | Vasodilator Agents | 1 | 2017 | 331 | 0.120 |
Why?
| | Disease Management | 1 | 2019 | 627 | 0.120 |
Why?
| | Shock, Cardiogenic | 1 | 2015 | 63 | 0.120 |
Why?
| | Drug Combinations | 1 | 2016 | 344 | 0.120 |
Why?
| | Arterial Occlusive Diseases | 1 | 2014 | 81 | 0.110 |
Why?
| | Stroke Volume | 3 | 2025 | 619 | 0.110 |
Why?
| | Chagas Cardiomyopathy | 1 | 2014 | 24 | 0.110 |
Why?
| | Prasugrel Hydrochloride | 1 | 2013 | 22 | 0.100 |
Why?
| | Insurance, Pharmaceutical Services | 1 | 2013 | 22 | 0.100 |
Why?
| | Contraindications | 1 | 2013 | 90 | 0.100 |
Why?
| | Heart Ventricles | 1 | 2018 | 792 | 0.100 |
Why?
| | Michigan | 1 | 2013 | 108 | 0.100 |
Why?
| | Program Evaluation | 1 | 2017 | 891 | 0.100 |
Why?
| | Drug Utilization Review | 1 | 2013 | 57 | 0.100 |
Why?
| | Diabetic Angiopathies | 1 | 2015 | 259 | 0.100 |
Why?
| | Blood Pressure | 1 | 2019 | 1776 | 0.100 |
Why?
| | Drug Utilization | 1 | 2013 | 170 | 0.100 |
Why?
| | Recurrence | 1 | 2015 | 1059 | 0.090 |
Why?
| | Hemorrhage | 1 | 2016 | 723 | 0.090 |
Why?
| | Medication Adherence | 1 | 2015 | 468 | 0.090 |
Why?
| | Societies, Medical | 1 | 2015 | 822 | 0.090 |
Why?
| | Catheters | 2 | 2022 | 72 | 0.090 |
Why?
| | Seizures | 1 | 2014 | 430 | 0.080 |
Why?
| | Quality Indicators, Health Care | 1 | 2013 | 310 | 0.080 |
Why?
| | Comorbidity | 1 | 2015 | 1624 | 0.080 |
Why?
| | Incidence | 3 | 2021 | 2808 | 0.080 |
Why?
| | Echocardiography | 2 | 2025 | 659 | 0.080 |
Why?
| | Hospital Mortality | 1 | 2013 | 903 | 0.070 |
Why?
| | Longitudinal Studies | 1 | 2015 | 2850 | 0.070 |
Why?
| | Young Adult | 2 | 2020 | 13163 | 0.060 |
Why?
| | Quality Improvement | 1 | 2013 | 1172 | 0.060 |
Why?
| | Bundle of His | 1 | 2023 | 18 | 0.050 |
Why?
| | Atrioventricular Node | 1 | 2021 | 15 | 0.050 |
Why?
| | Cardiac Electrophysiology | 1 | 2021 | 18 | 0.050 |
Why?
| | Tachycardia | 1 | 2021 | 58 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2025 | 5436 | 0.040 |
Why?
| | Animals | 1 | 2023 | 36862 | 0.040 |
Why?
| | Colorado | 2 | 2021 | 4527 | 0.040 |
Why?
| | Patient Readmission | 2 | 2016 | 703 | 0.040 |
Why?
| | Antithrombins | 1 | 2020 | 60 | 0.040 |
Why?
| | Tricuspid Valve | 1 | 2019 | 30 | 0.040 |
Why?
| | Artificial Intelligence | 1 | 2023 | 277 | 0.040 |
Why?
| | Physician-Patient Relations | 1 | 2024 | 548 | 0.040 |
Why?
| | Systole | 1 | 2019 | 191 | 0.040 |
Why?
| | Mitral Valve | 1 | 2019 | 89 | 0.040 |
Why?
| | Prognosis | 2 | 2019 | 4026 | 0.040 |
Why?
| | Interviews as Topic | 1 | 2021 | 770 | 0.040 |
Why?
| | Hospitalization | 2 | 2021 | 2214 | 0.040 |
Why?
| | Myocardial Ischemia | 1 | 2019 | 263 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2019 | 1063 | 0.030 |
Why?
| | Pilot Projects | 1 | 2021 | 1700 | 0.030 |
Why?
| | Reoperation | 1 | 2018 | 583 | 0.030 |
Why?
| | Medicare | 1 | 2021 | 758 | 0.030 |
Why?
| | Research Design | 1 | 2021 | 1128 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 1970 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2016 | 1260 | 0.020 |
Why?
| | Prevalence | 1 | 2019 | 2715 | 0.020 |
Why?
| | Child | 2 | 2022 | 21999 | 0.020 |
Why?
| | Disease Progression | 1 | 2019 | 2752 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 3283 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2021 | 5769 | 0.020 |
Why?
| | Cohort Studies | 1 | 2014 | 5726 | 0.010 |
Why?
| | Adolescent | 1 | 2022 | 21499 | 0.010 |
Why?
|
|
Sandhu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|